Welcome to our dedicated page for Oncolytics Biotech news (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech stock.
Oncolytics Biotech Inc (ONCY) is a clinical-stage biotech company advancing pelareorep, an innovative oncolytic virus immunotherapy targeting multiple cancer types. This dedicated news hub provides investors and researchers with centralized access to corporate developments and scientific progress updates.
Track critical updates including clinical trial results, regulatory milestones, and strategic partnerships. Our curated collection features press releases spanning Phase 2 breast cancer studies, pancreatic cancer research advancements, and manufacturing capacity expansions. Regular updates ensure timely awareness of key developments in HR+/HER2- metastatic breast cancer trials and other high-priority programs.
Discover verified information on pelareorep's mechanism of action, trial design specifics, and intellectual property developments. The resource eliminates the need by aggregating essential updates from randomized controlled studies to manufacturing quality initiatives. Bookmark this page for efficient monitoring of Oncolytics' progress in transforming cancer treatment through viral immunotherapy approaches.
Oncolytics Biotech presented two abstracts at the 2024 ASCO Annual Meeting that highlight the potential of pelareorep in treating metastatic pancreatic ductal adenocarcinoma (PDAC) and its immunotherapeutic mechanism of action.
The first abstract discusses a new cohort in the GOBLET study, which will test pelareorep combined with mFOLFIRINOX, with and without atezolizumab. This cohort is funded by a $5 million grant, expecting enrollment to start this quarter.
The second abstract highlights pelareorep's ability to induce tumor-infiltrating lymphocytes (TILs) expansion, correlating with improved tumor response across multiple cancers, providing further support for its use as a backbone immunotherapy.
On May 16, 2024, Oncolytics Biotech announced the voting results from its Annual General Meeting held on May 15, 2024. Representing 41.34% of outstanding shares, shareholders elected eight directors with the following votes: Patricia Andrews (84.78%), Deborah M. Brown (74.81%), Matthew C. Coffey (70.97%), Angela Holtham (77.53%), James T. Parsons (74.81%), Wayne Pisano (72.88%), Jonathan Rigby (76.81%), and Bernd R. Seizinger (81.49%).
Additionally, shareholders approved the number of directors at eight and reappointed the auditors for the coming year. For more details, refer to the management information circular at SEDAR.
Oncolytics Biotech (NASDAQ: ONCY) announced a preliminary collaboration with the Global Coalition for Adaptive Research (GCAR) to include pelareorep in a planned pancreatic cancer trial. The trial will use a combination therapy of checkpoint inhibition and chemotherapy, and aims to accelerate the development timeline while reducing costs. The adaptive Phase 2/3 design will assess multiple investigational therapies for metastatic pancreatic cancer, providing a potential registration pathway. Updated data from the GOBLET study showed a 62% objective response rate with pelareorep, nearly triple the historical control trials. This strategic collaboration is expected to advance the development of pelareorep to address urgent patient needs.
Oncolytics Biotech® reported first-quarter 2024 financial results and operational highlights including advancing pelareorep to registration-enabling studies, obtaining FDA Type C meeting for HR+/HER2- metastatic breast cancer, and anticipated milestones like overall survival data in H2 2024. The company has a cash position of $29.6 million providing runway into 2025.
Oncolytics Biotech Inc. has received regulatory clearance to evaluate pelareorep in combination with modified FOLFIRINOX and an anti-PD-L1 inhibitor in pancreatic cancer. The company will start enrollment in a new GOBLET study cohort, supported by a $5M grant from PanCAN, with the first patient expected to be enrolled in Q2 2024. The study aims to enhance pelareorep's potential in addressing pancreatic cancer and expand its role in providing benefits to patients.
Oncolytics Biotech® Inc. (NASDAQ: ONCY) will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference. Dr. Matt Coffey, the CEO, will be speaking at the event taking place on May 14-15, 2024, in New York. The company will also hold one-on-one investor meetings and provide a live webcast of the presentation on its website.
Oncolytics Biotech® announced a conference call and webcast to discuss corporate updates and financial results for the first quarter of 2024. The event will take place on May 9, 2024, at 4:30 p.m. ET.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
